Kailera Therapeutics Financial Statements
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.61+1.61 (+16.10%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kailera Therapeutics has no annual income statement on file yet, so quarterly figures are shown instead.
Kailera Therapeutics revenue and earnings
Kailera Therapeutics reported a net loss of $111.3 million. Diluted earnings per share came in at -$1.09.
Summary generated from market data by MetaCap's automated system. Methodology
Kailera Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 121.37M | 84.66M | 30.65M | 20.46M |
| Research & Development | 101.06M | 70.87M | 19.52M | 10.13M |
| Operating Income | -121.37M | -84.66M | -30.65M | -20.46M |
| Other Income (Expense) | 10.07M | 5.79M | 1.70M | 2.48M |
| Net Income | -111.31M | -78.86M | -28.95M | -17.98M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -1.09 | -3,650.00 | -28,947.00 | -17,983.00 |
| EPS (Diluted) | -1.09 | -3,650.00 | -28,947.00 | -17,983.00 |
| Shares Outstanding (Basic) | 102.23M | 21.61K | 1 | 1 |
| Shares Outstanding (Diluted) | 102.23M | 21.61K | 1 | 1 |
| EBITDA | -121.27M | -84.56M | -30.59M | -20.39M |
This table shows 4 quarterly periods of Kailera Therapeutics's income statement, from Q2 2026 back to Q? 2025, across 10 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow KLRA's reporting calendar. What is a income statement?